Octreotide
What the Research Actually Shows
Human: 1 studies, 4 groups · Animal: 0 · In Vitro: 0
The eight-amino-acid peptide that changed neuroendocrine tumor treatment — from symptom management to tumor growth control in one landmark trial
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Octreotide is an FDA-approved peptide drug used to treat certain hormone-producing tumors and a growth hormone disorder called acromegaly. It works by mimicking a natural brain hormone called somatostatin, which tells your body to stop releasing too many hormones. In 2009, a landmark study called PROMID proved something bigger: octreotide doesn't just control symptoms — it actually slows tumor growth. Patients with a type of cancer called neuroendocrine tumors went 14 months before their tumors grew, versus 6 months on placebo. That single trial turned octreotide from a symptom manager into a cancer-fighting drug. It's been used safely in millions of patients for over 30 years.
Octreotide is a synthetic cyclic octapeptide — eight amino acids arranged in a ring stabilized by a disulfide bridge — designed to mimic the natural hormone somatostatin-14. Where somatostatin itself is cleared from the bloodstream in roughly 2–3 minutes, octreotide persists for about 90 minutes after subcutaneous injection, and the depot formulation (Sandostatin LAR) provides sustained release over 28 days from a single intramuscular injection.
Developed by Sandoz (now Novartis), octreotide received FDA approval in 1988 for acromegaly and carcinoid syndrome symptom control. For two decades, it was used primarily as a hormonal suppression therapy — controlling the debilitating diarrhea, flushing, and hormonal surges produced by functional neuroendocrine tumors. It worked well in that role, controlling symptoms in 65–80% of patients.
The compound's significance expanded dramatically in 2009 when the PROMID trial demonstrated that octreotide LAR significantly prolonged time to tumor progression in metastatic midgut neuroendocrine tumors — 14.3 months versus 6.0 months with a hazard ratio of 0.34 (PMID 19858101). This was the first randomized controlled trial proving that a somatostatin analog could slow tumor growth, not just suppress hormone secretion.
Octreotide's story is the opening chapter of a remarkable three-part narrative in the Cancer and Oncology cluster: octreotide proved peptides could bind somatostatin receptors on tumors, lanreotide proved they could slow even nonfunctioning tumors, and Lutathera proved the same receptor-binding principle could deliver lethal radiation directly to cancer cells.
In This Article
Quick Facts: Octreotide at a Glance
Type
Synthetic cyclic octapeptide somatostatin analog (8 amino acids)
Also Known As
Sandostatin, Sandostatin LAR Depot, SMS 201-995, octreotide acetate
Generic Name
Octreotide acetate
Brand Name
Sandostatin (immediate-release SC), Sandostatin LAR Depot (long-acting IM)
Related Compounds
Lanreotide (same class, CLARINET trial), Lutathera (radiolabeled SSTR agonist), pasireotide (multi-receptor somatostatin analog)
WADA Status
Not on WADA Prohibited Lists
Molecular Weight
~1,019 Da
Peptide Sequence
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol) with Cys2-Cys7 disulfide bridge
Endogenous Origin
Synthetic analog of somatostatin-14 (SST-14), a 14-amino-acid neuropeptide produced in the hypothalamus, GI tract, and pancreas
Primary Molecular Function
Somatostatin receptor agonist (SSTR2 > SSTR5) — inhibits hormone secretion and cell proliferation in receptor-positive tumors
Active Fragment
Contains the somatostatin pharmacophore (Phe-Trp-Lys-Thr) in a stabilized cyclic framework — the minimal motif required for SSTR binding
Half-Life
~90 minutes (SC immediate-release); ~28 days effective duration (LAR depot via PLGA microspheres)
Clinical Programs
Multiple: acromegaly, carcinoid syndrome, GEP-NETs (PROMID), VIPomas, glucagonomas. Decades of clinical use in millions of patients
Route
Subcutaneous injection (Sandostatin, 2–3× daily) or intramuscular injection (LAR Depot, monthly)
FDA Status
Approved (1988): acromegaly, carcinoid syndrome. LAR approved for GEP-NETs. Standard of care in neuroendocrine oncology
Community Interest
Not a community-use compound. Prescription-only pharmaceutical used exclusively in clinical settings
Evidence Tier
1 Approved Drug
Verdict
Strong Foundation
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Octreotide?
Pronunciation: ok-TREE-oh-tide
Your body produces a hormone called somatostatin — a molecular brake pedal that tells virtually every secretory process in the body to slow down. Growth hormone release, insulin secretion, glucagon secretion, gastric acid production, bile flow — somatostatin suppresses them all. It is one of the most broadly inhibitory molecules in human physiology.
The problem with natural somatostatin is that it's gone almost as fast as it's made. With a half-life of roughly 2–3 minutes, somatostatin-14 is too short-lived to be useful as a drug. Researchers at Sandoz solved this by identifying the minimal amino acid sequence responsible for somatostatin's receptor binding — the Phe-Trp-Lys-Thr motif — and embedding it within a smaller, more metabolically stable cyclic framework. The result was octreotide: eight amino acids, a disulfide bridge for stability, and a half-life extended from minutes to roughly 90 minutes.
That engineering achievement, modest as it sounds, made possible an entire category of cancer therapy. Octreotide's ability to bind somatostatin receptor subtype 2 (SSTR2) — which is expressed on the surface of most well-differentiated neuroendocrine tumors — opened the door to symptom control, tumor growth inhibition, and eventually the targeted radiation delivery that Lutathera would achieve two decades later.
PLAIN ENGLISH
Octreotide is a synthetic version of a natural hormone that tells your body to stop releasing other hormones. Scientists made it last longer than the natural version, and then discovered it could do something the natural version never gets a chance to do: bind to receptors on certain tumor cells and slow their growth.
Origins and Discovery
The story of octreotide begins in the late 1970s at Sandoz Research Institute in Basel, Switzerland. Wilfried Bauer and colleagues set out to create a somatostatin analog that retained the hormone's therapeutic potential while overcoming its crippling pharmacokinetic limitations. Natural somatostatin suppressed growth hormone, insulin, and glucagon effectively — but its 2–3 minute half-life made clinical use impractical.
Through systematic structure-activity studies, the Sandoz team identified that the Phe-Trp-Lys-Thr sequence at positions 7–10 of somatostatin-14 was the pharmacophore — the minimum structural element required for receptor binding. They constructed a cyclic octapeptide incorporating this motif with D-amino acid substitutions (D-Phe, D-Trp) for protease resistance and a disulfide bridge (Cys2-Cys7) for conformational stability (PMID 6129881).
The resulting compound — SMS 201-995, later named octreotide — had a half-life of ~90 minutes (30-fold improvement), selective binding to SSTR2 and SSTR5, and retained the antisecretory activity of native somatostatin. Sandostatin received FDA approval in 1988, initially for acromegaly and carcinoid syndrome symptom control.
The depot formulation (Sandostatin LAR) followed, using biodegradable PLGA microspheres to encapsulate octreotide for sustained release over 28 days from a single intramuscular injection — transforming a twice-daily injection into a monthly treatment.
Mechanism of Action
Somatostatin Receptor Biology
Five somatostatin receptor subtypes (SSTR1–5) have been identified, all G-protein coupled receptors that inhibit adenylyl cyclase and activate phosphatases. Octreotide binds preferentially to SSTR2 (highest affinity) and SSTR5, with minimal activity at SSTR1, SSTR3, and SSTR4.
SSTR2 is the critical receptor for oncology applications. It is overexpressed on the surface of most well-differentiated neuroendocrine tumors — including carcinoid tumors, pancreatic NETs, pheochromocytomas, and pituitary adenomas. This receptor expression pattern is what makes octreotide both a therapeutic tool and a diagnostic one (OctreoScan imaging uses radiolabeled octreotide to locate SSTR2-positive tumors).
PLAIN ENGLISH
Think of SSTR2 as an address label on tumor cells. Not every cancer cell has this label, but neuroendocrine tumors almost always do. Octreotide is the mail carrier that recognizes this address — it delivers a "stop growing" message specifically to cells that display the label.
Antisecretory Mechanism
In functional neuroendocrine tumors (tumors that produce hormones causing symptoms), octreotide's SSTR2 activation inhibits the secretory machinery: - Inhibits exocytosis of hormone-containing granules - Reduces intracellular cAMP → decreased gene transcription of hormone products - Controls the debilitating diarrhea (serotonin suppression), flushing (serotonin and tachykinin suppression), and hypoglycemia (insulin suppression from insulinomas) or hyperglycemia (glucagon suppression from glucagonomas)
Antiproliferative Mechanism
The PROMID trial demonstrated that octreotide doesn't just suppress symptoms — it slows tumor cell division. The antiproliferative mechanisms operate through multiple pathways:
1. Direct cell cycle arrest: SSTR2 activation recruits the phosphatase SHP-1, which dephosphorylates key cell cycle regulators → G1 arrest 2. Apoptosis induction: SSTR2 activation triggers caspase-dependent apoptosis in some tumor cell lines 3. Indirect growth factor suppression: Octreotide inhibits secretion of IGF-1, VEGF, and EGF — growth factors that tumors use to feed their own growth (autocrine/paracrine loops) 4. Antiangiogenic effects: VEGF suppression reduces new blood vessel formation that tumors need to grow beyond a few millimeters
PLAIN ENGLISH
Octreotide fights tumors in two ways at once. First, it directly tells tumor cells to stop dividing by activating a "stop" signal inside the cell. Second, it cuts off the supply lines — reducing the growth factors and blood vessel formation that tumors need to expand. The combination of direct and indirect effects is why the PROMID trial showed such a strong result.
The LAR Depot: Engineering Sustained Exposure
The Sandostatin LAR formulation encapsulates octreotide within biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres. After intramuscular injection, the microspheres slowly degrade, releasing octreotide over approximately 28 days. Steady-state plasma concentrations are achieved after approximately three monthly injections.
This sustained-release profile is pharmacologically important: maintaining consistent SSTR2 occupancy over weeks provides continuous antiproliferative signaling, as opposed to the intermittent peaks and troughs of immediate-release dosing.
Mechanistic Comparison
vs. Lanreotide: Same receptor family but slightly different affinity profile (lanreotide has higher SSTR3 affinity). Lanreotide Autogel is a supersaturated solution forming a gel depot (self-injectable SC) vs. LAR's PLGA microspheres (healthcare-provider IM). Clinical efficacy is comparable; the CLARINET trial extended the antiproliferative indication to nonfunctioning NETs.
vs. Pasireotide (Signifor): Multi-receptor somatostatin analog binding SSTR1, 2, 3, and 5. Used in Cushing's disease and acromegaly resistant to octreotide. Higher hyperglycemia risk due to broader receptor activation.
vs. Lutathera (¹⁷⁷Lu-DOTATATE): Uses octreotide's SSTR2-binding principle but attaches a radioactive payload. Where octreotide delivers a "stop dividing" signal, Lutathera delivers lethal radiation. Same targeting, different warhead.
Key Research Areas and Studies
The PROMID Trial: The Watershed
Rinke et al. (2009) published the Placebo-controlled, double-blind, prospective, Randomized study On the effect of octreotide LAR in the control of tumor growth in patients with Metastatic neuroendocrine MIDgut tumors — PROMID (PMID 19858101).
This was the first randomized controlled trial to demonstrate that a somatostatin analog could inhibit tumor growth, not just control symptoms: - Design: Placebo-controlled, double-blind, Phase III - Population: 85 patients with metastatic midgut neuroendocrine tumors (both functional and nonfunctional) - Intervention: Octreotide LAR 30 mg IM monthly vs. placebo - Primary endpoint: Time to tumor progression (TTP) - Result: TTP 14.3 months (octreotide) vs. 6.0 months (placebo), HR 0.34 (95% CI 0.20–0.59, p=0.000072)
The hazard ratio of 0.34 meant a 66% reduction in the risk of tumor progression. For a disease with limited treatment options, this was transformative.
PLAIN ENGLISH
Before PROMID, octreotide was thought of as a symptom reliever — it controlled the diarrhea and flushing that neuroendocrine tumors cause. PROMID proved it does something more fundamental: it slows the tumors themselves. Patients on octreotide went more than twice as long before their tumors grew compared to placebo.
Acromegaly: Three Decades of Data
Octreotide has been the standard medical therapy for acromegaly (growth hormone-secreting pituitary adenomas) since the late 1980s. Clinical experience across thousands of patients demonstrates: - GH normalization (<2.5 ng/mL) in approximately 65% of patients - IGF-1 normalization in approximately 50–65% - Tumor shrinkage (>20% volume reduction) in approximately 30–50% of patients on primary medical therapy - Long-term safety profile well-characterized over 30+ years
Carcinoid Syndrome Symptom Control
The original approved indication. Octreotide controls carcinoid syndrome symptoms — diarrhea in 65–80% and flushing in 70–80% of patients. This is mediated primarily through SSTR2-dependent inhibition of serotonin and tachykinin secretion from carcinoid tumor cells.
The Somatostatin Story Arc
Octreotide established the fundamental principle: somatostatin receptors on neuroendocrine tumors can be therapeutically targeted with synthetic peptide analogs. This principle was then extended by lanreotide (CLARINET — proving antiproliferative effects in nonfunctioning tumors) and Lutathera (NETTER-1 — using the receptor as a homing beacon for targeted radiation). The three compounds represent successive chapters of the same biological insight.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Octreotide controls carcinoid symptoms"” | Established across 30+ years of clinical use. Controls diarrhea in 65–80% and flushing in 70–80% of patients. FDA-approved indication since 1988. | Supported |
| “"Octreotide slows tumor growth in NETs"” | PROMID (N=85): TTP 14.3 vs. 6.0 months, HR 0.34, p=0.000072 (PMID 19858101). Definitive RCT evidence. | Supported |
| “"Octreotide treats acromegaly"” | FDA-approved. Normalizes GH in ~65% and IGF-1 in ~50–65% of patients. Three decades of clinical data. | Supported |
| “"Octreotide cures neuroendocrine tumors"” | No. Octreotide slows tumor growth (cytostatic) but does not produce tumor regression in most patients. Complete responses are rare. Disease control, not cure. | Mixed Evidence |
| “"Octreotide works for all types of cancer"” | No. Efficacy is limited to SSTR2-positive tumors — primarily well-differentiated neuroendocrine tumors. Poorly differentiated NETs and most non-NET cancers do not express sufficient SSTR2 for octreotide to be effective. | Unsupported |
| “"Octreotide LAR is better than lanreotide"” | Head-to-head trials show comparable efficacy. Lanreotide's CLARINET trial extended the antiproliferative indication to nonfunctioning NETs; PROMID enrolled both functional and nonfunctional. Choice often depends on patient preference (self-injectable vs. healthcare-provider injection). | Mixed Evidence |
| “"Somatostatin analogs should be used in all NET patients"” | Current guidelines recommend SSAs for well-differentiated, SSTR-positive NETs with a Ki-67 index <20%. High-grade, poorly differentiated neuroendocrine carcinomas typically require platinum-based chemotherapy, not SSAs. | Mixed Evidence |
| “"Octreotide has minimal side effects"” | Common AEs: GI effects (nausea, diarrhea, steatorrhea), gallstones (15–30% long-term), glucose metabolism changes. Generally well-tolerated but not side-effect-free — gallbladder monitoring is recommended. | Mixed Evidence |
| “"Octreotide can prevent cancer in healthy people"” | No evidence supports chemopreventive use. All clinical data is in patients with established tumors or acromegaly. | Unsupported |
| “"Higher doses of octreotide work better"” | NETTER-1 used octreotide LAR 60 mg as the comparator arm — above the standard 30 mg — and this higher dose was clearly inferior to Lutathera. Dose-response for antiproliferative effect is not well-established beyond the standard 30 mg LAR dose. | Mixed Evidence |
| “"Octreotide is safe for long-term use"” | 30+ years of post-marketing safety data. Gallstone risk (15–30%) is the main long-term concern. Glucose monitoring needed. No increased cancer risk from the drug itself. Overall favorable long-term safety profile. | Supported |
| “"The PROMID trial was small and therefore unreliable"” | N=85 is modest, but the effect size was dramatic (HR 0.34) and statistically overwhelming (p=0.000072). The CLARINET trial (N=204) with lanreotide confirmed the SSA class antiproliferative effect. Small trial, large and consistent effect. | Unsupported |
The Human Evidence Landscape
Octreotide has one of the most extensive human evidence bases of any peptide on the Peptidings site. Decades of clinical use, multiple randomized controlled trials, post-marketing safety data from millions of patients, and integration into international treatment guidelines make this one of the best-characterized peptides in medicine.
Landmark Trials
PROMID (2009): 85 patients, placebo-controlled, double-blind. TTP 14.3 vs. 6.0 months, HR 0.34. First RCT proving SSA antiproliferative effect.
CLARINET (2014, lanreotide — same class): 204 patients, placebo-controlled, double-blind. PFS HR 0.47 in nonfunctioning GEP-NETs. Confirmed and extended the SSA antiproliferative principle to tumors without hormonal symptoms.
NETTER-1 (2017, Lutathera — SSA backbone): 229 patients. Lutathera + octreotide LAR 30 mg vs. octreotide LAR 60 mg alone. PFS HR 0.21. Established that SSTR-targeting can be weaponized with radiation.
Acromegaly Evidence Base
Hundreds of clinical studies spanning 30+ years. GH normalization data, tumor shrinkage data, long-term safety data. Octreotide is referenced in every major acromegaly guideline worldwide (PMID 29562532).
Registry and Real-World Data
Large patient registries (CLARINET FORTE, RADIANT, ENETS registry) provide real-world effectiveness and safety data beyond the controlled trial setting, confirming that PROMID results translate to routine clinical practice.
PLAIN ENGLISH
Octreotide isn't a compound where you have to squint at small studies and hope the results are real. The evidence base is enormous — landmark clinical trials, decades of use in millions of patients, international guidelines recommending it as standard of care. This is what "Strong Foundation" means on Peptidings.
Safety, Risks, and Limitations
Gastrointestinal Effects
The most common side effects are GI-related: nausea, abdominal pain, diarrhea, and steatorrhea (fatty stools from reduced pancreatic enzyme secretion). These are pharmacological effects of somatostatin receptor activation in the GI tract and are usually manageable. Most patients experience GI effects initially that improve with continued treatment.
Gallbladder Disease
Cholelithiasis (gallstones) develops in 15–30% of patients on long-term octreotide therapy. The mechanism: somatostatin receptor activation reduces gallbladder contractility and alters bile composition, promoting sludge and stone formation. Ultrasound monitoring of the gallbladder is recommended at baseline and periodically during treatment.
PLAIN ENGLISH
Octreotide slows down your gallbladder along with everything else it slows down. Over time, this can cause gallstones in roughly one in five patients. Doctors monitor for this with periodic ultrasounds — it's a known, manageable risk.
Glucose Metabolism
Octreotide suppresses both insulin and glucagon secretion. The net effect on glucose is variable — some patients develop hyperglycemia, others hypoglycemia — depending on the balance of insulin/glucagon suppression and the patient's baseline glucose regulation. Glucose monitoring is essential, particularly in diabetic patients.
Cardiac Effects
Bradycardia and conduction abnormalities occur rarely. QT prolongation has been reported at supra-therapeutic doses. ECG monitoring is recommended in patients with cardiac risk factors.
Injection Site Reactions
Subcutaneous: pain, erythema. LAR intramuscular: nodule formation, injection site discomfort. The LAR injection requires proper technique — gluteal IM injection into a deep tissue depot.
Hypothyroidism
Rare TSH suppression, usually subclinical. Thyroid function monitoring is recommended for long-term use.
What Octreotide Does NOT Do
Octreotide does not cure cancer. It slows tumor growth in SSTR2-positive neuroendocrine tumors — a cytostatic effect. Eventually, most tumors will progress despite octreotide therapy, requiring escalation to Lutathera, everolimus, or other agents. Setting appropriate expectations is essential: octreotide buys time, it does not eliminate disease.
Legal and Regulatory Status
Octreotide is an FDA-approved prescription pharmaceutical available only through healthcare providers.
FDA Approvals: - Sandostatin (1988): Acromegaly, severe diarrhea/flushing from carcinoid tumors, profuse watery diarrhea from VIPomas - Sandostatin LAR Depot: Long-term maintenance therapy for acromegaly and carcinoid syndrome; treatment of GEP-NETs
International: Approved by EMA and regulatory agencies worldwide. Included in WHO Essential Medicines List for neuroendocrine tumors and acromegaly.
Generic availability: Octreotide (immediate-release) is available as generic. LAR depot generic versions are available in some markets.
WADA does not prohibit octreotide. It is not a performance-enhancing substance.
Research Protocols and Formulation Considerations
Octreotide is a well-characterized pharmaceutical with established manufacturing, stability, and administration protocols.
Immediate-release (Sandostatin): Supplied as 0.05, 0.1, 0.2, 0.5, and 1.0 mg/mL solutions for subcutaneous injection. Store at 2–8°C (35–46°F). Protect from light. Stable for 14 days at room temperature.
Depot (Sandostatin LAR): Supplied as kits with lyophilized microspheres (10, 20, or 30 mg) and diluent. Requires reconstitution immediately before injection. Administered by deep intramuscular gluteal injection. Store at 2–8°C (35–46°F).
Dosing in Published Research
All octreotide dosing is FDA-approved and well-characterized through clinical trials and decades of clinical experience.
Acromegaly: - Sandostatin SC: Initial 50 mcg three times daily; titrate to 100–500 mcg three times daily based on GH/IGF-1 response - Sandostatin LAR: 20 mg IM every 4 weeks; titrate to 10–30 mg based on clinical response
Carcinoid Syndrome: - Sandostatin SC: 100–600 mcg/day in 2–4 divided doses - Sandostatin LAR: 20 mg IM every 4 weeks; may increase to 30 mg based on symptom control
GEP-NETs (Antiproliferative — PROMID dosing): - Sandostatin LAR: 30 mg IM every 4 weeks
Carcinoid Crisis Prevention: - Sandostatin SC: 250–500 mcg IV bolus before procedures that risk carcinoid crisis (surgery, embolization)
Dosing in Self-Experimentation Communities
WHY NO COMMUNITY DOSING SECTION?
Octreotide is an FDA-approved prescription medication. Dosing is established by clinical guidelines and managed by prescribing physicians. Community “dosing protocols” for prescription medications can be dangerous and are not appropriate to present here. Consult your healthcare provider for dosing information.
Octreotide is not a community-use compound. It is a prescription pharmaceutical available only through healthcare providers. There is no self-experimentation community for octreotide, and the compound is not available from peptide vendors.
All use is clinical, under physician supervision, with established protocols, monitoring schedules, and dose titration guidelines.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Octreotide combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Octreotide with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Target/Receptor | Landmark Trial | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|---|
| Octreotide | Cyclic octapeptide SSA (8 aa, disulfide) | Tier 1 — Approved Drug | Strong Foundation | SSTR2/5 agonist → antisecretory + antiproliferative | SSTR2, SSTR5 | PROMID (N=85, TTP HR 0.34) | Phase III RCT; 30+ years clinical use | Approved 1988 (acromegaly, carcinoid, GEP-NETs) | Not prohibited | Gallstones (15–30%); glucose metabolism effects |
| Lanreotide | Cyclic octapeptide SSA (8 aa, disulfide) | Tier 1 — Approved Drug | Strong Foundation | SSTR2/3/5 agonist → antiproliferative in nonfunctioning NETs | SSTR2, SSTR3, SSTR5 | CLARINET (N=204, PFS HR 0.47) | Phase III RCT; 15+ years post-approval | Approved 2007 (acromegaly); 2014 (GEP-NETs) | Not prohibited | Same class as octreotide; gallstones; glucose effects |
| Lutathera | Radiolabeled peptide (¹⁷⁷Lu-DOTATATE) | Tier 1 — Approved Drug | Strong Foundation | SSTR2-targeted PRRT → intracellular beta-radiation → DNA damage | SSTR2 | NETTER-1 (N=229, PFS HR 0.21) | Phase III RCT + 504-pt registry | Approved January 2018 (SSTR+ GEP-NETs) | Not prohibited | Myelosuppression; MDS/AML risk (~2%); requires nuclear medicine facility |
| Motixafortide | Cyclic peptide (14 aa) | Tier 2 — Clinical Trials | Reasonable Bet | CXCR4 antagonist → stem cell mobilization + tumor immune sensitization | CXCR4 | GENESIS (N=122, 92.5% vs. 26.2% mobilization) | Phase III + Phase 2a (N=199 total) | Not approved (Phase 3 complete) | Not prohibited | No FDA approval yet; competes with approved plerixafor |
| Melflufen | Peptide-drug conjugate (dipeptide-melphalan) | Tier 2 — Clinical Trials | Thin Ice | Aminopeptidase-activated intracellular melphalan release → DNA crosslinking | Aminopeptidase N (CD13) | OCEAN (N=495, PFS HR 0.79 but OS HR 1.104) | Phase III RCT (N=652 total) | Approved Feb 2021; WITHDRAWN Feb 2024 | Not prohibited | Worse OS than comparator; severe myelosuppression; market withdrawal |
| Cilengitide | Cyclic RGD pentapeptide (5 aa) | Tier 2 — Clinical Trials | Thin Ice | αvβ3/αvβ5 integrin antagonist → antiangiogenic | αvβ3, αvβ5 integrins | CENTRIC (N=545, OS HR 1.02) | Phase III RCT (N=891 total) | Not approved; development discontinued | Not prohibited | Definitive Phase III failure (HR 1.02); development abandoned |
style="color:#0F4C5C;font-size:28px;font-weight:700;margin:48px 0 16px 0;line-height:1.2">Frequently Asked Questions
What types of cancer does octreotide treat?
Does octreotide cure neuroendocrine tumors?
How does octreotide compare to lanreotide?
What is the relationship between octreotide and Lutathera?
What are the most common side effects?
How do doctors determine if octreotide will work for a specific patient?
Is octreotide available as a generic?
How was the PROMID trial designed?
Is octreotide used for anything besides cancer?
Does octreotide affect growth hormone in patients without acromegaly?
How long do patients typically stay on octreotide?
Is octreotide a peptide?
Summary of Key Findings
Octreotide is a landmark peptide therapeutic — one of the first synthetic peptides to prove that cancer treatment could be achieved through receptor-targeted molecular therapy rather than cytotoxic chemotherapy. Its journey from symptom management tool (1988) to antiproliferative cancer drug (2009, PROMID) to the precursor of targeted radiation therapy (Lutathera, 2018) represents one of the most complete translational arcs in modern oncology.
The PROMID trial remains the defining study: 85 patients, placebo-controlled, time to tumor progression more than doubled (14.3 vs. 6.0 months, HR 0.34). This result, confirmed by the CLARINET trial with lanreotide in nonfunctioning NETs, established somatostatin analogs as the first-line standard of care for well-differentiated, SSTR-positive neuroendocrine tumors.
Safety over 30+ years of clinical use is well-characterized. Gallstones (15–30%), GI effects, and glucose metabolism changes are the primary concerns — all manageable with appropriate monitoring. The risk-benefit ratio is firmly favorable for indicated patients.
Octreotide is not available through peptide vendors and is not part of the self-experimentation community. It is a prescription pharmaceutical that requires physician supervision, appropriate diagnostic workup (somatostatin receptor imaging), and ongoing monitoring.
PLAIN ENGLISH
Octreotide is the story of what happens when peptide science meets disciplined clinical development. A small molecule — eight amino acids — proved that a peptide could be engineered to target a specific receptor on cancer cells and slow tumor growth. Three decades, millions of patients, landmark trials, and international guidelines later, octreotide remains the backbone of neuroendocrine tumor treatment. This is what "Strong Foundation" looks like.
Verdict Recapitulation
Octreotide earns the highest confidence rating on the Peptidings scale. FDA-approved for multiple indications. Backed by the PROMID RCT with an unambiguous result. Three decades of post-marketing safety data. Standard of care in every major guideline. The compound that proved peptides could fight cancer.
For readers considering Octreotide, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Octreotide
Further Reading and Resources
If you want to go deeper on Octreotide, the evidence landscape for cancer & oncology peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Cancer & Oncology Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Octreotide — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Rinke A, Müller HH, Schade-Brittinger C, et al. (2009). "Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group." J Clin Oncol, 27(28), 4656–4663. PMID 19858101
- Hofland LJ, Lamberts SWJ. (2003). "The pathophysiological consequences of somatostatin receptor internalization and resistance." Endocr Rev, 24(1), 28–47. PMID 12970106
- Bauer W, Briner U, Doepfner W, et al. (1982). "SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action." Life Sci, 31(11), 1133–1140. PMID 6129881
- Caplin ME, Pavel M, Ćwikła JB, et al. (2014). "Lanreotide in metastatic enteropancreatic neuroendocrine tumors." N Engl J Med, 371(3), 224–233. PMID 25099546
- Strosberg J, El-Haddad G, Wolin E, et al. (2017). "Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors." N Engl J Med, 376(2), 125–135. PMID 28076709
- Melmed S, Bronstein MD, Chanson P, et al. (2018). "A Consensus Statement on acromegaly therapeutic outcomes." Nat Rev Endocrinol, 14(9), 552–561. PMID 29562532
DISCLAIMER
Octreotide is an FDA-approved prescription medication. The information presented in this article is for educational purposes only. Off-label uses discussed here may not be supported by the same level of evidence as the approved indications. Always follow the guidance of your prescribing physician.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 11, 2026. Next scheduled review: October 08, 2026.